Loomis, Sayles & Company
XLRN

Loomis, Sayles & Company’s Acceleron Pharma XLRN Stock Holding History

Loomis, Sayles & Company’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-94,406
Closed -$16.2M – 941
2021
Q3 		$16.2M Buy
+94,406
New +$12.3M 0.02% 330
2021
Q1 		– Sell
-93
Closed -$12K – 918
2020
Q4 		$12K Buy
+93
New +$10.9K ﹤0.01% 705
2017
Q1 		– Sell
-370,424
Closed -$9.45M – 1063
2016
Q4 		$9.45M Buy
+370,424
New +$11.7M 0.02% 444
2015
Q2 		– Sell
-357,413
Closed -$13.6M – 956
2015
Q1 		$13.6M Sell
357,413
-24,392
-6% -$970K 0.04% 430
2014
Q4 		$14.9M Sell
381,805
-19,365
-5% -$675K 0.04% 428
2014
Q3 		$12.1M Sell
401,170
-10,611
-3% -$299K 0.04% 463
2014
Q2 		$14M Buy
411,781
+123,407
+43% +$4.13M 0.04% 450
2014
Q1 		$9.95M Buy
+288,374
New +$13M 0.03% 496

Loomis, Sayles & Company's XLRN Position: Q4 2021 in Review

Loomis, Sayles & Company sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 94,406 shares — an estimated $16.2M sold.

Loomis, Sayles & Company first reported a position in XLRN in Q1 2014 and held it in 8 quarters. The position peaked at $16.2M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Loomis, Sayles & Company reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 94,406 Acceleron Pharma shares in Q4 2021, an estimated $16.2M.
  • Loomis, Sayles & Company first reported a position in Acceleron Pharma in Q1 2014 and held it in 8 quarters.
  • Loomis, Sayles & Company's Acceleron Pharma position peaked at $16.2M in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Loomis, Sayles & Company's 13F filing for Q4 2021, filed 14 Feb 2022.